Why Is Rifampin So Hard to Find? [Explained for 2026]

If you or a loved one has been prescribed rifampin and you're having trouble filling the prescription, you're not alone. Rifampin — a cornerstone antibiotic in the treatment of tuberculosis (TB) and several other serious bacterial infections — has been difficult to obtain in certain formulations, particularly as an injectable. Here's an honest, up-to-date look at why rifampin is hard to find in 2026 and what you can do about it.

What Is Rifampin Used For?

Rifampin (brand name Rifadin, also known as rifampicin internationally) is a rifamycin antibiotic that has been a critical tool in global infectious disease treatment for decades. It is FDA-approved for:

Active tuberculosis (TB) — as part of a combination regimen with isoniazid, pyrazinamide, and ethambutol

Latent TB infection (LTBI) — 4-month rifampin monotherapy (4R regimen) is a preferred CDC regimen

Meningococcal carrier state — to eliminate Neisseria meningitidis from the nose and throat

Haemophilus influenzae type B (Hib) prophylaxis for close contacts of infected individuals

Leprosy (Hansen's disease) in combination regimens

Because rifampin plays such an irreplaceable role in TB treatment — particularly for drug-susceptible TB — any disruption to its supply has serious public health implications.

Is Rifampin Currently in Shortage?

As of June 2026, rifampin injection (the IV formulation) is in active shortage. There are two main products affected:

Sanofi's Rifadin IV (600 mg/10 mL): Discontinued from manufacturing. This product is listed as unavailable with no expected return to the market.

Mylan Institutional (Viatris) rifampin injection (600 mg/10 mL): Currently unavailable due to a delay in shipping, with next release expected in July 2026. Wholesalers may have limited inventory.

Importantly, rifampin oral capsules (150 mg and 300 mg) are NOT in a formal FDA-listed shortage and are generally available at most retail pharmacies. If your prescription is for capsules, supply is typically much easier to find.

Why Is the Rifampin Injection Shortage Happening?

The shortage of rifampin injection stems from two interconnected problems common to the pharmaceutical supply chain:

1. Manufacturing Discontinuation

Sanofi's brand-name Rifadin IV has been permanently discontinued. When a major manufacturer exits the market for a niche injectable, the remaining supplier(s) often cannot immediately scale up to meet total demand — leaving hospitals and clinics scrambling.

2. Shipping Delays

The Mylan/Viatris product — the remaining commercial source of rifampin injection in the U.S. — experienced delays in shipping as of mid-2026. These delays may be related to quality review holds, production scheduling, or logistics issues that are common in sterile injectable manufacturing.

What About the Nitrosamine Issue?

In August 2020, the FDA identified nitrosamine impurities (specifically 1-methyl-4-nitrosopiperazine, or MNP) in certain samples of rifampin. The FDA and manufacturers have been investigating this issue since then. While the FDA has been developing testing methods and establishing safe exposure limits, these quality concerns can sometimes slow production as manufacturers update their processes to ensure compliance.

Who Is Most Affected by This Shortage?

The rifampin injection shortage most directly affects patients who cannot take oral medications, including:

Hospitalized patients with severe TB infections who require IV administration

Patients undergoing treatment for TB meningitis or other serious infections where IV is clinically preferred

Patients with gastrointestinal conditions preventing oral absorption

For most outpatient TB and LTBI patients who can swallow capsules, the oral formulation remains available and fully effective.

Is Rifampin Available at My Local Pharmacy?

Oral rifampin capsules (150 mg, 300 mg) are stocked by most major chain and independent pharmacies in the U.S. However, "stocked" doesn't always mean "in stock right now" — pharmacies sometimes run out between shipments, face local allocation constraints, or have only one strength available. Even for oral capsules, availability can vary by location and can change week to week.

This is where a service like medfinder can save you significant time and stress. Instead of calling pharmacy after pharmacy yourself, medfinder contacts pharmacies in your area to find out which ones can fill your rifampin prescription — then texts you the results.

What Can You Do If You Can't Find Rifampin?

Here are practical steps to take:

Don't stop treatment without consulting your doctor. Stopping TB therapy mid-course is dangerous and can lead to drug resistance.

Ask your provider about alternatives. Rifabutin (Mycobutin) or rifapentine (Priftin) may be substitutable in some cases, though this requires medical guidance.

Contact your local public health TB clinic. Many health departments provide rifampin and other TB drugs for free through public health programs.

Try a different pharmacy. Independent pharmacies and specialty pharmacies sometimes maintain stock when chains do not.

Use medfinder. medfinder calls local pharmacies on your behalf to find out exactly which ones have your medication in stock, saving you hours of legwork.

Will the Shortage Get Better?

The Mylan/Viatris rifampin injection shortage is expected to ease in July 2026 based on current FDA shortage database information. The Sanofi discontinuation is permanent, however, which means the injectable market will rely solely on Viatris going forward — making future supply disruptions more likely unless additional manufacturers enter the market.

For oral capsule availability, the outlook is better — no FDA shortage is currently listed for oral rifampin. However, patients in some areas may still face intermittent local stock-outs.

Related Resources

How to find Rifampin in stock near you — tools and tips

Rifampin shortage update: What patients need to know in 2026